Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
NitroMed, Inc. (NASDAQ: NTMD) today reported financial results for the fourth quarter and the year ended December 31, 2008. Total revenues for the three months ended December...
NitroMed, Inc. (NASDAQ: NTMD) said today that on Friday, January 9, 2009, NitroMed received a letter from Deerfield Management increasing Deerfield?s unsolicited proposal to...
NitroMed, Inc. (NASDAQ: NTMD) said today that Deerfield Management has responded to NitroMed?s communication regarding the company?s willingness to discuss Deerfield?s prior...
NitroMed, Inc. (NASDAQ: NTMD) said today that it has received an unsolicited proposal from Deerfield Management to acquire the company for $0.50 per share in cash. Deerfield...
NitroMed, Inc. (NASDAQ: NTMD) and Archemix Corp., a privately-held biopharmaceutical company working to develop aptamer-based therapeutics, announced today that they have...
NitroMed, Inc. (NASDAQ:NTMD) today announced that JHP Pharmaceuticals, LLC, a privately held specialty pharmaceutical company, has agreed to acquire substantially all of the...
NitroMed, Inc. (NASDAQ: NTMD) reported that on September 16, 2008 it received a letter from The NASDAQ Stock Market?s Listing Qualifications Department providing notification...
NitroMed, Inc. (NASDAQ: NTMD) today reported financial results for its second fiscal quarter and year to date ended June 30, 2008. NitroMed is the maker of BiDil? (isosorbide...
NitroMed, Inc. (NASDAQ: NTMD), announced today that on Tuesday August 5, 2008 it will release financial results for the Company?s second fiscal quarter ended June 30, 2008...
NitroMed, Inc. (NASDAQ: NTMD) today reported financial results for the fiscal quarter ended March 31, 2008. NitroMed is the maker of BiDil? (isosorbide dinitrate/hydralazine...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
